Examinando por Autor "de Azeredo Siqueira, Rodrigo"
Mostrando 1 - 1 de 1
Resultados por página
Opciones de ordenación
Ítem Type 2 diabetes in latin America: recommendations on the flash glucose monitoring system(BioMed Central Ltd, 2024-12) Krakauer, Marcio; Gómez, Ana M.; Almeda-Valdes, Paloma; Manrique, Helard; Ruiz Morosini, María Lidia; Godoy Jorquera, Gonzalo; Nunes Salles, João Eduardo; Sanhueza Costa, David; de Azeredo Siqueira, Rodrigo; Faradji, Raquel N.; Rincón Ramírez, Alex; Ré, Matías; Fériz Bonelo, Karen; Proietti, Adrián; Lavalle-González, Fernando J.Objective: To establish recommendations through the consensus of a Latin American experts panel on the use of the flash glucose monitoring system (fCGM) in people living with type 2 diabetes mellitus (T2DM) regarding the benefits and challenges of using the fCGM. Methods: An executive committee of experts was created, comprised by a panel of fifteen physicians, including endocrinologists and internal medicine physicians, with expertise in management of adult patients with T2DM. The experts were from various countries: Colombia, Chile, Peru, Mexico, Argentina, and Brazil. The modified Delphi method was used, considering a consensus level of at least 80% of the participants. A seventeen-item instrument was developed to establish recommendations on the use of fCGM in patients with T2DM in Latin American. Results: The number of glucose scans recommended per day with the fCGM for patients managed with oral antidiabetic drugs or basal insulin was a median of 6 scans per day, and for those managed with multiple insulin doses, a median of 10 scans per day was recommended. Additionally, a holistic and individualized management approach was recommended, taking into account new treatment directions and identifying patients who would benefit from the use of the fCGM. Conclusion: Continuous use of the fCGM is recommended for people living with T2DM, regardless of their type of treatment. These metrics must be evaluated individually for each patient profile. © The Author(s) 2024.